NYSE · Healthcare · Diagnostics & Research · USA
IQVIA Holdings Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
IQVIA supplies the life sciences and healthcare sectors with research capabilities, commercial insights and healthcare intelligence. The company delivers actionable information through advanced analytics, healthcare-grade AI and proprietary health data covering sales, prescriptions, medical records and genomics. IQVIA serves biotech, pharmaceutical and medical device companies, researchers, government agencies and healthcare payers worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the IQVIA Holdings Inc stock.
Overvalued: intrinsic value $177.31 per share, market price $265.88, margin of safety -50.0% (as of 2026-10-19).
Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $177.31; the price of $265.88 is 50% above that value, and 74% of that value comes from beyond year five.
Leak Score: 58/100 on 12 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
2 more in this industry show a wider margin of safety.
IQV is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $177.31; the price of $265.88 is 50% above that value, and 74% of that value comes from beyond year five.
$177.31 per share (as of the 2026-10-19 close), against a market price of $265.88. That is a margin of safety of -50.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
58 out of 100, which we rate "Weak Signal", on 12 of 12 value investing signals.